Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Calaspargase pegol - Servier

Next Previous
Drug Profile

Calaspargase pegol - Servier

Alternative Names: ASPARLAS; Cal-PEG; EZN-2285; Oncaspar-IV; S9-5015; SC-PEG E. coli L-asparaginase; Scalasparagase pegol; SHP-663

Latest Information Update: 02 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Enzon Pharmaceuticals
  • Developer Children's Oncology Group; Dana-Farber Cancer Institute; Leadiant Biosciences; National Cancer Institute (USA); Servier
  • Class Amidohydrolases; Antineoplastics; Polyethylene glycols
  • Mechanism of Action Aspartate-ammonia ligase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Precursor cell lymphoblastic leukaemia-lymphoma
  • New Molecular Entity No

Highest Development Phases

  • Marketed Precursor cell lymphoblastic leukaemia-lymphoma
  • Phase II Haematological malignancies
  • No development reported Acute myeloid leukaemia

Most Recent Events

  • 18 Feb 2026 Institut de Recherches Internationales Servier terminates a phase II/III SPARK-ALL trial for Precursor cell lymphoblastic leukaemia lymphoma (Newly diagnosed, In adults) in USA (IV) due to sponsor's decision (NCT04817761)
  • 18 Nov 2025 Launched for Precursor cell lymphoblastic leukaemia-lymphoma (In adolescents, In children) in Canada (IV)
  • 30 Apr 2022 Phase-II clinical trials in Haematological malignancies (IV) before April 2022 (Servier pipeline, June 2022)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top